Cheng Yingjie,Shan Ci,Shi Hanhan,et al.Research advances of MicroRNAs in the diagnosis,differential diagnosis and prognostic evaluation of hepatoblastoma[J].Journal of Clinical Pediatric Surgery,2019,18(08):660-663.[doi:10.3969/j.issn.1671-6353.2019.08.009]
MicroRNAs在肝母细胞瘤诊断、鉴别诊断及预后评估中的研究进展
- Title:
- Research advances of MicroRNAs in the diagnosis,differential diagnosis and prognostic evaluation of hepatoblastoma
- Keywords:
- Hepatoblastoma; MicroRNAs; Biomarker; Molecular classification; Diagnosis; Prognostic Evaluation
- 分类号:
- R735.7;R730.45;R730.7
- 摘要:
- 肝母细胞瘤（hepatoblastoma，HB）在儿童恶性肿瘤中较为罕见，多见于5岁以下儿童，男性较多见，约占儿童原发性肝脏恶性肿瘤的80%。其中仅95%的肝母细胞瘤存在甲胎蛋白（α-fetoprotein，AFP）异常升高，而且与病理类型、肿瘤分期等相关性不大。仅通过异常升高的AFP水平进行肝母细胞瘤诊断、鉴别诊断及预后评估存在一定的局限性。目前已有诸多研究发现miRNAs在HB的发生、发展中起重要作用，且具有高度组织特异性、保守性和时序性，在不同病理类型的HB中mRNAs呈特异性表达。因此，有望联合AFP与microRNAs进行HB的分子分型，组成HB的分子指纹，用于肝母细胞瘤诊断、鉴别诊断及预后评估，具有重要的参考意义。
- Abstract:
- As an extremely rare type of pediatric malignant carcinoma,hepatoblastoma (HB) is commonly found in boys aged under 5 years.It accounts for proximately 80% of primary malignant hepatic tumors in children.An abnormal elevation of α-fetoprotein (AFP) occurred only in 95% of HB children.And it was not significantly correlated with pathological type or tumor staging.There is some limitation for making the diagnosis,differential diagnosis and prognostic evaluation of hepatoblastoma merely through an abnormal elevation of AFP level.As demonstrated by many studies,playing important roles in the occurrence and development of HB,miRNAs had high levels of tissue specificity,conservatism and sequence and were specifically expressed in different pathological types of HB.Thus hopefully a combined biomarker of AFP and microRNAs may be utilized for molecular typing of HB.And HB fingerprint shall provide vital references for the diagnosis,differential diagnosis and prognostic evaluation of HB.
参考文献/References:
1 金晟,施诚仁.儿童肝母细胞瘤研究现状[J].临床儿科杂志,2014,32(10):988-992.DOI:10.3969/j.issn.1000-3606.2014.10.31.Jin S,Shi CR.Current research of hepatoblastoma in children[J].J Clin Ped,2014,32(10):988-992.DOI:10.3969/j.issn.1000-3606.2014.10.31.
2 Heck JE,Meyers TJ,Lombardi C,et al.Case-control study of birth characteristics and the risk of hepatoblastoma[J].Cancer Epidemiol,2013,37(4):390-395.DOI:10.1016/j.canep.2013.03.004.
3 Turcotte LM,Georgieff MK,Ross JA,et al.Neonatal Medical Exposures and Characteristics of Low Birth Weight Hepatoblastoma Cases:A Report From the Children’s Oncology Group[J].Pediatr Blood Cancer,2014,61(11):2018-2023.DOI:10.1002/pbc.25128.
4 Duffy KA,Deardorff MA,Kalish JM.The utility of alpha-fetoprotein screening in Beckwith-Wiedemann syndrome[J].Am J Med Genet A,2017,173(3):581-584.DOI:10.1002/ajm g.a.38068.
5 Allan BJ,Parikh PP,Diaz S,et al.Predictors of survival and incidence of hepatoblastoma in the paediatric population[J].HPB (Oxford),2013,15(10):741-746.DOI:10.1111/hpb.12112.
6 Salvatore M,Magrelli A,Taruscio D.The role of microRNAs in the biology of rare disease[J].Int J Mol Cell Med,2011,12(10):6733-6742.DOI:10.3390/ijms12106733.
7 Li J,Li X,Kong X,et al.MiRNA-26b inhibits cellular proliferation by targeting CDK8 in breast cancer[J].Int J Clin Exp Med,2014,7(3):558-565.
8 Huang L,Li F,Deng P,et al.MicroRNA-223 promotes tumor progression in lung cancer A549cells via activation of the NF-κB signaling pathway[J].Oncol Res,2016,24(6):405-413.DOI:10.3727/096504016x14685034103437.
9 Alhaidari AA,Syk I,Thorlacius H.MiR-155-5p positively regulates CCL17-induced colon cancer cell migration by targeting RhoA.[J].Oncotarget,2017,8(9):14887-14896.DOI:10.18632/oncotarget.14841.
10 Min P,Li W,Zeng D,et al.A single nucleotide variant in microRNA-1269a promotes the occurrence and process of hepatocellular carcinoma by targeting to oncogenes SPATS2L and LRP6[J].Bull Cancer,2017,104(4):311-320.DOI:10.1016/j.bulcan.2016.11.021.
11 Cristóbal I,Sanz-Álvarez M,Luque M,et al.The role of MicroRNAs in hepatoblastoma tumors[J].Cancers,2019,11(3):409.DOI:10.3390/cancers11030409.
12 王椋,赵春华.miRNA与癌症发生[J].癌症进展,2011,9(2):124-127.DOI:10.3969/j.issn.1672-1535.2011.02.003.Wang L,Zhao CH.miRNA and carcinogenesis[J].Oncol Prog,2011,9(2):124-127.DOI:10.3969/j.issn.1672-1535.2011.02.003.
13 陶肇堃,王珊.小儿肝母细胞瘤的诊断与治疗进展[J].世界临床医学,2016,10(13):100-101.Tao ZK,Wang S.Progress in diagnosis and treatment of infantile hepatoblastom[J].The World Clinical Medicine,2016,10(13):100-101.
14 Gyugos M,Lendvai G,Kenessey I,et al.MicroRNA expression might predict prognosis of epithelial hepatoblastoma[J].Virchows Archiv,2014,464(4):419-427.DOI:10.1007/s00428-014-1549-y.
15 Magrelli A,Azzalin G,Salvatore M,et al.Altered microRNA Expression Patterns in Hepatoblastoma Patients[J].Transl Oncol,2009,2(3):157-163.DOI:10.1593/tlo.09124.
16 Liu W,Sheng C,Bing L.Diagnostic and prognostic values of serum exosomal microRNA-21in children with hepatoblastoma:a Chinese population-based study[J].Pediatr Surg Int,2016,32(11):1059-1065.DOI:10.1007/s00383-016-3960-8.
17 Jiao C,Jiao X,Zhu A,et al.Exosomal miR-34s panel as potential novel diagnostic andprognostic biomarker in patients with hepatoblastoma[J].Pediatr Surg,2017,52(4):618-624.DOI:10.1016/j.jpedsurg.2016.09.070.
18 杨美,郭晓东,周艳贤,等.miRNA-492在肝癌中表达变化的研究[J].现代生物医学进展,2013,13(10):1908-1910.Yang M,Guo XD,Zhou YX,et al.Expression of miRNA-492 in hepatocellcular carcinoma[J].Progress in Moder Biomedicine,2013,13(10):1908-1910.
19 von Frowein J,Hauck SM,Kappler R,et al.MiR-492 regulates metastatic properties of hepatoblastoma via CD44[J].Liver Int,2018,38(7):1280-1291.DOI:10.1111/liv.13687.
20 Salvatore M,Magrelli A,Flamini V,et al.Hepatoblastoma andmicroRNA-483 Two Forms and One Outcome[J].Genet Syndr Gene Ther,2016,7:278.DOI:10.4172/2157-7412.1000278.
21 Roebuck DJ,Perilongo G.Hepatoblastoma:an oncological review[J].Pediatr Radiol,2006,36(3):183-186.DOI:10.1007/s00247-005-0064-3.
22 Ismail H,Broniszczak D,Kaliciński P,et al.Changing treatment and outcome of children with hepatoblastoma:analysis of a single center experience over the last 20 years[J].J Pediatr Surg,2012,47(7):1331-1339.DOI:10.1016/j.jpedsurg.2011.11.073.
23 Zhang Y,Zhang WL,Huang DS,et al.Clinical efficacy and prognosis factors for advanced hepatoblastoma in children:a 6-year retrospective study[J].Asian Pac J Cancer Prev,2013,14(8):4583-4589.DOI:10.7314/apjcp.2013.14.8.4583.
24 Qiao GL,Li L,Cheng W,et al.Predictors of survival after resection of children with hepatoblastoma:A single Asian center experience[J].Eur J Surh Oncol,2014,40(11):1533-1539.DOI:10.1016/j.ejso.2014.07.033.
25 Qiao GL,Chen Z,Wang C,et al.Pure fetal histology subtype was associated with better prognosis of children with hepatoblastoma:A Chinese population-based study[J].J Gastroenterol Hepatol,2015,31(3):621-627.DOI:10.1111/jgh.13165.
26 Jiao C,Zhu A,Jiao X,et al.Combined low miR-34s are associated with unfavorable prognosis in children with hepatoblastoma:A Chinese population-based study[J].J Pediatr Surg,2016,51(8):1355-1361.DOI:10.1016/j.jpedsurg.2016.02.091.
27 Ruby JG,Jan C,Player C,et al.Large-scale sequencing reveals 21U-RNAs and additional microRNAs and endogenous siRNAs in C.elegans[J].Cell,2006,127(6):1193.DOI:10.1016/j.cell.2006.10.040.
28 Cairo S,Wang Y,de Reyniès A,Duroure K,et al.Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer[J].Proc Natl Acad Sci,2010,107(47):20471.DOI:10.1073/pnas.1009009107.
相似文献/References:
[1]陈立才,李朋飞,黄一敏,等. 抗EpCAM单克隆抗体治疗肝母细胞瘤的动物实验研究[J].临床小儿外科杂志,2019,18(01):63.
Chen Licai,Li Pengfei,Huang Yimin,et al. Targeting therapy of antiEpCAM monoclonal antibody in hepatoblastoma animal model.[J].Journal of Clinical Pediatric Surgery,2019,18(08):63.
[2]王焕民.重视安全与历练,提高小儿肝胆肿瘤诊治水平[J].临床小儿外科杂志,2023,22(12):1101.[doi:10.3760/cma.j.cn101785-202310061-001]
Wang Huanmin.Further improving the diagnoses and treatments of pediatric hepatobiliary tumors[J].Journal of Clinical Pediatric Surgery,2023,22(08):1101.[doi:10.3760/cma.j.cn101785-202310061-001]
[3]唐湘莲,刘登辉,李勇.儿童肝母细胞瘤治疗难点与思考[J].临床小儿外科杂志,2023,22(12):1104.[doi:10.3760/cma.j.cn101785-202310045-002]
Tang Xianglian,Liu Denghui,Li Yong.Difficulties and reflections on proper treatments of hepatoblastoma in children[J].Journal of Clinical Pediatric Surgery,2023,22(08):1104.[doi:10.3760/cma.j.cn101785-202310045-002]
[4]林宇,王焕民,杨深,等.经导管动脉栓塞术治疗肝母细胞瘤破裂的初步探索[J].临床小儿外科杂志,2023,22(12):1109.[doi:10.3760/cma.j.cn101785-202310011-003]
Lin Yu,Wang Huanmin,Yang Shen,et al.Preliminary exploration of transcatheter arterial embolization for ruptured hepatoblastoma[J].Journal of Clinical Pediatric Surgery,2023,22(08):1109.[doi:10.3760/cma.j.cn101785-202310011-003]
[5]徐晓钢,曾纪晓,罗媛圆,等.全球首例不阻断第一肝门的机器人肝切除术治疗儿童肝母细胞瘤[J].临床小儿外科杂志,2023,22(12):1114.[doi:10.3760/cma.j.cn101785-202307016-004]
Xu Xiaogang,Zeng Jixiao,Luo Yuanyuan,et al.Robotic hepatectomy in a 14-month-old child of hepatoblastoma without the first hepatic portal control:a first case report in the world[J].Journal of Clinical Pediatric Surgery,2023,22(08):1114.[doi:10.3760/cma.j.cn101785-202307016-004]
[6]刘百慧,解鲁璐,姚伟,等.联合肝脏离断和门静脉结扎二步肝切除术治疗儿童巨大肝母细胞瘤[J].临床小儿外科杂志,2023,22(12):1119.[doi:10.3760/cma.j.cn101785-202309028-005]
Liu Baihui,Xie Lulu,Yao Wei,et al.Application of associating liver partition and portal vein ligation during two-stage hepatectomy for massive hepatoblastoma[J].Journal of Clinical Pediatric Surgery,2023,22(08):1119.[doi:10.3760/cma.j.cn101785-202309028-005]
[7]杨丽媛,顾松,王晶,等.m6A修饰在肝母细胞瘤中的研究进展[J].临床小儿外科杂志,2023,22(12):1130.[doi:10.3760/cma.j.cn101785-202209040-007]
Yang Liyuan,Gu Song,Wang Jing,et al.Research advances of m6A modification in hepatoblastoma[J].Journal of Clinical Pediatric Surgery,2023,22(08):1130.[doi:10.3760/cma.j.cn101785-202209040-007]
[8]周恩卿,董瑞.黄连素在儿童胚胎源性肿瘤中的研究进展[J].临床小儿外科杂志,2023,22(12):1135.[doi:10.3760/cma.j.cn101785-202208042-008]
Zhou Enqing,Dong Rui.Research advances of berberine in pediatric embryonal tumors[J].Journal of Clinical Pediatric Surgery,2023,22(08):1135.[doi:10.3760/cma.j.cn101785-202208042-008]
[9]杨维,刘珊,任清华,等.多灶性肝母细胞瘤手术切除的单中心研究[J].临床小儿外科杂志,2024,(06):543.[doi:10.3760/cma.j.cn101785-202310006-007]
Yang Wei,Liu Shan,Ren Qinghua,et al.Hepatectomy for multifocal hepatoblastoma:a single-center report[J].Journal of Clinical Pediatric Surgery,2024,(08):543.[doi:10.3760/cma.j.cn101785-202310006-007]
备注/Memo
收稿日期:2018-03-28。
基金项目:国家临床重点专科建设项目（编号：国卫办医函[2013]544号）；上海市科学技术委员会医学引导（编号：134119a7600）；上海交通大学"医工交叉研究基金"（编号：YG2015MS36）
通讯作者:顾松,Email:gusongscmc@163.com